Overview: Progression-free survival as an endpoint in clinical trials with solid tumors

Clinical Cancer Research

Volumn 19, Issue 10, 2013, Pages 2607-2612

  Korn, Ronald L ^a   Crowley, John J ^b  

^a Imaging Endpoints Core Lab   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; CLINICAL EVALUATION; CLINICAL OBSERVATION; CLINICAL TRIAL (TOPIC); CYTOSTASIS; DIGITAL IMAGING; DRUG ACTIVITY; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION PROCESSING; INTERNAL BIAS; MEDICAL DECISION MAKING; METHODOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SOLID TUMOR; STANDARDIZATION; STATISTICAL ANALYSIS; TREATMENT RESPONSE; TUMOR VOLUME; VOLUMETRY; BIOASSAY; DISEASE COURSE; DISEASE FREE SURVIVAL; NEOPLASMS; PATHOLOGY; PROCEDURES;

DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84878071809     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2934     Document Type: Review

References (26)

1. Sridhara R, Mandrekar SJ, Dodd LE. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials. Clin Cancer Res 2013;19: 2613-20.
2. Chen D-G, Sun J, Peace KE. Interval-censored time-to-event data. Boca Roton (FL): CRC Press; 2013.
3. Finkelstein DM. A proportional hazards model for interval-censored failure time data. Biometrics 1986;42:845-54.
4. Qi Y, Allen Ziegler AL, Hillman SL, Redman MW, Schild SE, Gandara DR, et al. Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer. Cancer 2012;118:5358-65.
5. Carroll KJ. Analysis of progression-free survival in oncology trials: Some common statistical issues. Pharm Stat 2007;6:99-113.
6. Bhattacharya S, Fyfe G, Gray RJ, Sargent DJ. Role of sensitivity analyses in assessing progression-free survival in late stage oncology trials. J Clin Oncol 2009;27:5958-64.
7. Sullivan DC, Schwartz LH, Zhao B. The imaging viewpoint: how imaging affects determination of progression-free survival. Clin Cancer Res 2013;19:2621-8.
8. Villaruz LC, Socinski MA. The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res 2013;19:2629-36.
9. Maitland M. Volumes to learn: advancing therapeutics with innovative computed tomography image data analysis. Clin Cancer Res 2010;16: 4493-5.
10. Sharma MR, Maitland ML, Ratain MJ. RECIST: No longer the sharpest tool in the oncology clinical trials toolbox. Cancer Res 2012;72: 5145-9.
11. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15: 257-60.
12. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-6.
13. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in Neuro-Oncology Working Group. J Clin Oncol 2010;28:1963-72.
14. Mozley PD, Schwartz LH, Bendtsen C, Zhao B, Petrick N, Buckler AJ. Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. Ann Oncol 2010;21:1751-5.
15. Zhao B, Schwartz LH, Moskowitz CS, Ginsberg MS, Rizvi NA, Kris MG. Lung cancer: computerized quantification of tumor response-initial results. Radiology 2006;241:892-8.
16. Chang V, Narang J, Schultz L, Issawi A, Jain R, Rock J, et al. Computer-aided volumetric analysis as a sensitive tool for the management of incidental meningiomas. Acta Neurochir (Wien) 2012;154:589-97.
17. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006;6: 409-14.
18. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 2007;99:1455-61.
19. Amit O, Mannino F, Stone AM, Bushnell W, Denne J, Helterbrand J, et al. Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis. Eur J Cancer 2011;47: 1772-8.
20. Tang PA, Pond GR, Chen EX. Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. Ann Oncol 2010;21:19-26.
21. Zhang JJ, Zhang L, Chen H, Murgo AJ, Dodd LE, Pazdur R, et al. Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials. Clin Cancer Res 2013;19: 2637-45.
22. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumors treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-9.
23. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-440.
24. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007;25:5218-24.
25. Sidhu R, Rong A, Dahlberg S. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials. Clin Cancer Res 2013;19:969-76.
26. Redman MW, Goldman BH, LeBlanc M, Schott A, Baker LH. Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clin Cancer Res 2013;19:2646-56.